Abstract
Abstract Background Ubrogepant is an oral, small-molecule calcitonin gene–related peptide receptor antagonist for acute migraine treatment. Methods We conducted a randomized trial to evaluate the e...
Cite
CITATION STYLE
APA
Dodick, D. W., Lipton, R. B., Ailani, J., Lu, K., Finnegan, M., Trugman, J. M., & Szegedi, A. (2019). Ubrogepant for the Treatment of Migraine. New England Journal of Medicine, 381(23), 2230–2241. https://doi.org/10.1056/nejmoa1813049
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free